9.71
price down icon4.24%   -0.43
pre-market  プレマーケット:  10.85   1.14   +11.74%
loading
前日終値:
$10.14
開ける:
$9.92
24時間の取引高:
252.19K
Relative Volume:
1.32
時価総額:
$172.22M
収益:
$1.54M
当期純損益:
$-78.54M
株価収益率:
-1.6243
EPS:
-5.978
ネットキャッシュフロー:
$-64.50M
1週間 パフォーマンス:
+3.41%
1か月 パフォーマンス:
+21.22%
6か月 パフォーマンス:
-33.54%
1年 パフォーマンス:
+86.37%
1日の値動き範囲:
Value
$9.69
$10.38
1週間の範囲:
Value
$9.46
$10.66
52週間の値動き範囲:
Value
$5.12
$20.56

Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile

Name
名前
Corbus Pharmaceuticals Holdings Inc
Name
セクター
Healthcare (1110)
Name
電話
617-963-0103
Name
住所
500 RIVER RIDGE DRIVE, NORWOOD, MA
Name
職員
36
Name
Twitter
@corbuspharma
Name
次回の収益日
2026-03-10
Name
最新のSEC提出書
Name
CRBP's Discussions on Twitter

Compare CRBP vs VRTX, REGN, ARGX, ALNY, INSM

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
CRBP icon
CRBP
Corbus Pharmaceuticals Holdings Inc
9.71 172.22M 1.54M -78.54M -64.50M -5.978
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
431.86 109.85B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
760.27 80.38B 14.34B 4.50B 3.77B 41.56
ARGX icon
ARGX
Argen X Se Adr
765.43 47.60B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
319.52 42.63B 3.71B 313.75M 465.38M 2.2571
INSM icon
INSM
Insmed Inc
163.03 35.19B 606.42M -1.28B -997.58M -6.403

Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-07-30 再開されました B. Riley Securities Buy
2025-02-28 開始されました William Blair Outperform
2024-12-02 開始されました Piper Sandler Overweight
2024-07-30 開始されました Wedbush Outperform
2024-07-22 再開されました H.C. Wainwright Buy
2024-06-26 開始されました B. Riley Securities Buy
2024-06-03 繰り返されました Oppenheimer Outperform
2024-05-13 開始されました RBC Capital Mkts Outperform
2024-03-06 アップグレード Jefferies Hold → Buy
2020-09-08 ダウングレード BTIG Research Buy → Neutral
2020-09-08 ダウングレード Jefferies Buy → Hold
2020-09-08 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2020-09-08 ダウングレード ROTH Capital Buy → Neutral
2020-07-07 開始されました ROTH Capital Buy
2020-06-17 開始されました BTIG Research Buy
2020-03-26 開始されました Nomura Buy
2019-04-05 開始されました Jefferies Buy
2019-03-20 開始されました Oppenheimer Outperform
2019-01-11 繰り返されました Cantor Fitzgerald Overweight
2018-12-26 開始されました H.C. Wainwright Buy
2018-12-07 開始されました RBC Capital Mkts Outperform
2018-10-24 開始されました B. Riley FBR Buy
2018-01-19 開始されました Raymond James Outperform
2017-12-14 繰り返されました Cantor Fitzgerald Overweight
2017-11-08 繰り返されました Noble Financial Buy
2017-09-29 再開されました Noble Financial Buy
2017-03-30 繰り返されました Cantor Fitzgerald Overweight
2016-11-15 繰り返されました JMP Securities Mkt Outperform
2016-11-11 繰り返されました Noble Financial Buy
すべてを表示

Corbus Pharmaceuticals Holdings Inc (CRBP) 最新ニュース

pulisher
Apr 07, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Apr 07, 2026
pulisher
Apr 07, 2026

Jefferies reiterates Corbus Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada

Apr 07, 2026
pulisher
Apr 07, 2026

Corbus reaches FDA agreement on development path for cancer drug CRB-701 - MSN

Apr 07, 2026
pulisher
Apr 07, 2026

Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive EdgeCorbus Pharmaceutical - Benzinga

Apr 07, 2026
pulisher
Apr 07, 2026

Corbus Pharmaceuticals Secures FDA Alignment on Accelerated Approval Path for CRB-701 in Head and Neck and Cervical Cancer 1 - Minichart

Apr 07, 2026
pulisher
Apr 07, 2026

Corbus Pharmaceuticals (CRBP) Aligns with FDA on CRB-701 Study P - GuruFocus

Apr 07, 2026
pulisher
Apr 07, 2026

Corbus Aligns With FDA on CRB-701 Registrational Path - TipRanks

Apr 07, 2026
pulisher
Apr 07, 2026

Corbus Pharmaceuticals Holdings, Inc. secures U.S. FDA alignment on CRB-701 study for HNSCC and cervical cancer - Traders Union

Apr 07, 2026
pulisher
Apr 07, 2026

FDA backs Corbus (NASDAQ: CRBP) CRB-701 registrational plans in HNSCC and cervical cancer - Stock Titan

Apr 07, 2026
pulisher
Apr 07, 2026

Corbus Pharmaceuticals announces broad alignment with FDA on registration path for CRB-701 in second-line HNSCC and cervical cancer - marketscreener.com

Apr 07, 2026
pulisher
Apr 07, 2026

Two cancer trials move ahead after FDA aligns on Corbus plan - Stock Titan

Apr 07, 2026
pulisher
Apr 06, 2026

Mizuho raises Corbus Pharmaceuticals stock price target on CRB-701 By Investing.com - Investing.com Canada

Apr 06, 2026
pulisher
Apr 03, 2026

(CRBP) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Apr 03, 2026
pulisher
Apr 02, 2026

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch

Apr 02, 2026
pulisher
Apr 02, 2026

Corbus Pharmaceuticals (NASDAQ: CRBP) seeks approval to expand equity plan and confirm pay policies - stocktitan.net

Apr 02, 2026
pulisher
Apr 02, 2026

Corbus Pharmaceuticals Holdings (3371.SG) stock price, news, quote and history - uk.finance.yahoo.com

Apr 02, 2026
pulisher
Apr 02, 2026

Corbus Pharmaceuticals Holdings, Inc. advances next-gen ADC targeting Nectin-4 in aggressive cancers - Traders Union

Apr 02, 2026
pulisher
Apr 02, 2026

Mizuho raises Corbus Pharmaceuticals stock price target on updated CRB-701 assumptions - Investing.com Canada

Apr 02, 2026
pulisher
Apr 02, 2026

CRBP Stock Price, Quote & Chart | CORBUS PHARMACEUTICALS HOLDI (NASDAQ:CRBP) - ChartMill

Apr 02, 2026
pulisher
Apr 01, 2026

CRBP PE Ratio & Valuation, Is CRBP Overvalued - Intellectia AI

Apr 01, 2026
pulisher
Mar 31, 2026

CEO Change: What is the cash position of Corbus Pharmaceuticals Holdings Inc2026 Opening Moves & High Accuracy Buy Signal Tips - baoquankhu1.vn

Mar 31, 2026
pulisher
Mar 30, 2026

Published on: 2026-03-31 10:02:36 - baoquankhu1.vn

Mar 30, 2026
pulisher
Mar 30, 2026

Aug Shorts: Can Corbus Pharmaceuticals Holdings Inc ride the EV waveWeekly Trend Summary & Daily Technical Forecast Reports - baoquankhu1.vn

Mar 30, 2026
pulisher
Mar 30, 2026

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch

Mar 30, 2026
pulisher
Mar 28, 2026

STU:3371 PB Ratio: 1.04 — 73% Below Median - gurufocus.com

Mar 28, 2026
pulisher
Mar 27, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch

Mar 27, 2026
pulisher
Mar 27, 2026

CRBP SEC FilingsCorbus Pharmaceu 10-K, 10-Q, 8-K Forms - stocktitan.net

Mar 27, 2026
pulisher
Mar 25, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch

Mar 25, 2026
pulisher
Mar 25, 2026

Corbus Pharmaceuticals (NASDAQ: CRBP) files $300M shelf to sell equity, debt - Stock Titan

Mar 25, 2026
pulisher
Mar 25, 2026

Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Crosses Above 50-Day Moving AverageTime to Sell? - MarketBeat

Mar 25, 2026
pulisher
Mar 24, 2026

Corbus Pharmaceuticals Holdings Repeat Insider Selling Not A Positive Indicator - simplywall.st

Mar 24, 2026
pulisher
Mar 23, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch

Mar 23, 2026
pulisher
Mar 23, 2026

Corbus Pharmaceuticals Holdings, Inc. to present CRB-913 oral CB1 inverse agonist at BMO Summit - Traders Union

Mar 23, 2026
pulisher
Mar 23, 2026

[EFFECT] Corbus Pharmaceuticals Holdings, Inc. SEC Filing - Stock Titan

Mar 23, 2026
pulisher
Mar 23, 2026

How (CRBP) Movements Inform Risk Allocation Models - Stock Traders Daily

Mar 23, 2026
pulisher
Mar 22, 2026

If You Invested $1,000 in Corbus Pharmaceu (CRBP) - Stock Titan

Mar 22, 2026
pulisher
Mar 19, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Mar 19, 2026
pulisher
Mar 19, 2026

Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit - Sahm

Mar 19, 2026
pulisher
Mar 18, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Mar 18, 2026
pulisher
Mar 16, 2026

Corbus Pharmaceuticals Holdings Inc. stock rises Monday, still underperforms market - MarketWatch

Mar 16, 2026
pulisher
Mar 14, 2026

Prosight Management LP Decreases Stock Position in Corbus Pharmaceuticals Holdings, Inc. $CRBP - MarketBeat

Mar 14, 2026
pulisher
Mar 14, 2026

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Mar 14, 2026
pulisher
Mar 13, 2026

Dermatomyositis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Octapharma, Argenx, AstraZeneca, Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharma, Holdings - Barchart

Mar 13, 2026
pulisher
Mar 13, 2026

Dermatomyositis Market: Strong Pharma Growth Forecast Through - openpr.com

Mar 13, 2026
pulisher
Mar 12, 2026

HC Wainwright Issues Negative Forecast for CRBP Earnings - MarketBeat

Mar 12, 2026
pulisher
Mar 12, 2026

Trading Systems Reacting to (CRBP) Volatility - Stock Traders Daily

Mar 12, 2026
pulisher
Mar 11, 2026

Analysts Offer Insights on Healthcare Companies: Medpace Holdings (MEDP), Revolution Medicines (RVMD) and Corbus Pharmaceuticals (CRBP) - The Globe and Mail

Mar 11, 2026
pulisher
Mar 11, 2026

Corbus Pharmaceuticals (NASDAQ: CRBP) files $300M shelf registration - Stock Titan

Mar 11, 2026
pulisher
Mar 11, 2026

How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33% - Yahoo Finance

Mar 11, 2026
pulisher
Mar 11, 2026

Research Analysts Offer Predictions for CRBP FY2030 Earnings - MarketBeat

Mar 11, 2026
pulisher
Mar 10, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch

Mar 10, 2026

Corbus Pharmaceuticals Holdings Inc (CRBP) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$27.75
price down icon 0.47%
$50.11
price up icon 2.75%
$46.87
price down icon 0.95%
$89.62
price down icon 1.82%
ONC ONC
$303.82
price up icon 0.44%
$163.03
price down icon 0.48%
大文字化:     |  ボリューム (24 時間):